The most commonly reported side effects of infigratinib include fatigue, stomatitis, and off label use, based on 66 FDA adverse event reports from 2019 to 2023.
Percentages show how often each reaction appears relative to total reports for infigratinib.
These are voluntary reports and do not establish that infigratinib caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside infigratinib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
53.0% of infigratinib adverse event reports involve female patients and 30.3% involve male patients. The largest age group is adult at 54%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking infigratinib when the adverse event was reported.
Showing 15 of 20 indications
Infigratinib is sold under the brand name Truseltiq.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.